The FDA’s updated general wellness guidance brings new clarity to how low-risk digital health tools are evaluated in research. Rather than changing the definition, it sharpens expectations for how these products function in practice, especially during FDA inspections in clinical trials and IRB oversight. But what does it mean for sponsors and IRBs, practically?
This article answers that question, reviewing:
- What has changed in the FDA general wellness guidance, including clearer boundaries around claims, user experience, and device-like functionality
- Why disclaimers alone are no longer sufficient and how product design can influence participant understanding and risk
- How sponsors and CROs can avoid “general wellness” ambiguity to strengthen chances of regulatory approval
The bottom line? How a product is experienced matters as much as how it is described.
